Symbol06160
Company NameBEIGENE
ISINKYG1146Y1017
Listing DateAug 8, 2018
Issue Price108.00
Shares Offered65.60M share(s)
FoundedJun 28, 2018
Registered AddressCayman Islands
Chairmanleiqiang ou
Secretaryqingling zhou
Audit InstitutionErnst & Young, Ernst & Young LLP, Ernst & Young AG, Ernst & Young AG
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeThe Neighbors of Mourant Governance Services (Cayman) Limited 94 Solaris Avenue Camana Bay Grand Cayman KY1-1108 Cayman Islands
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden Phase 1, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees10500
MarketHong Kong motherboard
Phone+1 (781) 801-1800;1 (877) 828-5568
Fax010-85148699
Emailir@beigene.com
Business BeiGene Ltd is a global biotechnology company dedicated to discovering and developing oncology treatments for cancer patients around the world. The company has discovered and developed three approved drugs, including BRUKINSA, a small molecule inhibitor of Bruton's tyrosine kinase to treat various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for various solid tumors and blood cancers; and pAMIParib, a selective small molecule inhibitor of polyADP ribose polymerase 1 (PARP1) and PARP2. The company has obtained approval to sell BRUKINSA in the US, the People's Republic of China (China), the European Union, the United Kingdom, Canada, Australia, and other international markets; sell tiralizumab in the EU and China; and sell pamipanib in China. It also focuses on commercializing cancer drugs such as XGEVA, BLINCYTO, KYPROLIS, etc. in China under the exclusive license of Amgen Inc.